NCT04179630View on ClinicalTrials.gov

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 8, 2019

Primary Completion Date

December 4, 2019

Study Completion Date

December 14, 2019

Conditions
Impaired Renal Function
Interventions
BIOLOGICAL

Aldafermin (NGM282)

Single 3 mg dose

Trial Locations (1)

33014

NGM Clinical Study Site, Miami

Sponsors
All Listed Sponsors
lead

NGM Biopharmaceuticals, Inc

INDUSTRY